As of Sep 20
| -0.25 / -2.22%|
The 3 analysts offering 12-month price forecasts for Stemline Therapeutics Inc have a median target of 34.00, with a high estimate of 41.00 and a low estimate of 11.00. The median estimate represents a +209.09% increase from the last price of 11.00.
The current consensus among 4 polled investment analysts is to Buy stock in Stemline Therapeutics Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.